Absolute Benefits From Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors

Article Medicine, General & Internal

Empagliflozin in Patients with Chronic Kidney Disease

William G. Herrington et al.

Summary: Empagliflozin therapy reduces the risk of disease progression or cardiovascular death in patients with chronic kidney disease.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Review Endocrinology & Metabolism

Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression

Jose M. Rodriguez-Valadez et al.

Summary: This study investigated whether patients with varying risks differ in cardiovascular and renal benefits from GLP-1RA and SGLT2i. The results showed that the relative effects of novel diabetes drugs are preserved across baseline cardiovascular risk, while the absolute benefits increase at higher risks, especially for heart failure. This suggests a need for baseline risk assessment tools to identify variation in absolute treatment benefits and improve decision-making.

DIABETES CARE (2023)

Add to Collection

Article Endocrinology & Metabolism

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023

Nuha A. ElSayed et al.

DIABETES CARE (2023)

Add to Collection

Article Endocrinology & Metabolism

Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials

Ana Rita Leite et al.

Summary: This study aimed to investigate the effect of GLP-1 receptor agonists on the risk of cardiovascular events in overweight or obese adults without diabetes. The meta-analysis of placebo-controlled trials showed that GLP-1 RA treatment significantly reduced the risk of cardiovascular events in these patients.

DIABETES OBESITY & METABOLISM (2022)

Add to Collection

Article Medicine, General & Internal

SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

Muthiah Vaduganathan et al.

Summary: This study conducted a meta-analysis of the therapeutic effects of SGLT2 inhibitors in heart failure patients, showing that these drugs can significantly reduce the risk of cardiovascular death and hospitalization for heart failure in heart failure patients, demonstrating their importance in foundational treatment.

LANCET (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis

Darren K. McGuire et al.

Summary: SGLT2 inhibitors were found to reduce the risk of major adverse CV events and showed significant heterogeneity in associations with CV death. The most consistent benefit of this class of drugs was a reduction in risk for heart failure and kidney outcomes, with heart failure risk reduction being the most consistent observation across the trials.

JAMA CARDIOLOGY (2021)

Add to Collection

Review Endocrinology & Metabolism

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Naveed Sattar et al.

Summary: The meta-analysis showed that GLP-1 receptor agonists can reduce the risk of major adverse cardiovascular events, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes, regardless of structural homology.

LANCET DIABETES & ENDOCRINOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US

Lauren A. Eberly et al.

Summary: This study showed that Black and female patients as well as those with low socioeconomic status were less likely to receive SGLT2 inhibitor treatment among patients with type 2 diabetes in the US.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Health Care Sciences & Services

Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US

Lauren A. Eberly et al.

Summary: This study highlights the racial, ethnic, sex, and socioeconomic inequities related to the use of glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes in the US. Despite an increase in GLP-1 RA use, disparities persist with lower usage rates among Asian, Black, Hispanic, and low-income patients. Lowering barriers to GLP-1 RA use is crucial to address documented inequities in cardiovascular outcomes in the US.

JAMA HEALTH FORUM (2021)

Add to Collection

Letter Medicine, General & Internal